Tag Archive for: antibody Tcell engager

HQ of Boehringer IngelheimBoehringer Ingelheim
Partnership

Boehringer Ingelheim in US$570m deal with CDR-Life

Boehringer Ingelheim has licenced global rights for CDR111, an antibody-based trispecific M-gager to treat autoimmune diseases from  CDR-Life, Inc. CDR111 is an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset.  

Read more